← Eichor
Condition: Secondary Central Nervous System Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Secondary Central Nervous System Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Phase 1/Phase 2 · 1 location(s) · James Rubenstein · NCT05351593A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07137494Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Phase 1/Phase 2 · 5 location(s) · Tong Chen, MD · NCT05698147Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT05011045SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ
NA · 1 location(s) · Ruijin Hospital · NCT07191431Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07416890Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Phase 1 · 1 location(s) · Juan P. Alderuccio, MD · NCT06730542DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Samsung Medical Center · NCT06552559A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Phase 1 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT070828683'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Phase 1/Phase 2 · 3 location(s) · Jonsson Comprehensive Cancer Center · NCT05256641AI-assisted Diagnosis of Malignant Brain Tumors
Phase N/A · 2 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07198256PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07410520National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Phase 2 · 1 location(s) · Baptist Health South Florida · NCT05681195CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/Phase 2 · 35 location(s) · Children's Oncology Group · NCT04870944Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphom
Phase 1 · 3 location(s) · University of Utah · NCT06607549Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Phase 2 · 1 location(s) · Hyungwoo Cho · NCT07062627A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 62 location(s) · Nurix Therapeutics, Inc. · NCT05131022[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
Phase 1/Phase 2 · 2 location(s) · Pentixapharm AG · NCT06132737
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.